Understanding the chemical nuances of key intermediates is fundamental to advancing pharmaceutical research and development. NINGBO INNO PHARMCHEM CO.,LTD. is pleased to present insights into the chemistry of (R)-2-Methylbut-3-Enoic Acid (CAS No. 20626-49-7), a compound whose specific molecular structure and properties make it invaluable in the synthesis of novel pharmaceuticals.

The molecule of (R)-2-Methylbut-3-Enoic Acid possesses a distinct chiral center and a reactive enoic acid functional group. This specific structure, with a molecular formula of C5H8O2 and a molecular weight of 100.12 g/mol, provides the necessary scaffolding for complex organic synthesis. The 'R' configuration at the chiral center is particularly critical for its role as a pharmaceutical intermediate, ensuring stereospecificity in the synthesis of enantiomerically pure drugs.

Its utility is perhaps best illustrated in the synthesis of Milvexian, where the precise arrangement of atoms in (R)-2-Methylbut-3-Enoic Acid dictates the stereochemistry of the final Factor XIa inhibitor. This level of detail in chemical synthesis is crucial for producing drugs with targeted therapeutic effects and minimizing off-target interactions. The compound's classification as a chemical medicine intermediate underscores its broad applicability in scientific research and drug manufacturing.

NINGBO INNO PHARMCHEM CO.,LTD. focuses on delivering (R)-2-Methylbut-3-Enoic Acid that meets stringent chemical specifications. The high purity (>98%) and certifications (GMP, ISO 9001, FDA) are not just quality markers but essential components that enable chemists to pursue complex synthetic strategies with confidence. By understanding and appreciating the chemistry of this intermediate, researchers can unlock new possibilities in drug discovery and contribute to the development of future medicines.